Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AGN - Allergan plc


Previous close
193.09
193.090   100.000%

Share volume: 0
Last Updated: Fri 19 Jun 2020 10:01:39 PM CEST
Pharmaceuticals: Generic: 0.65%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
36%
Profitability 19%
Dept financing 15%
Liquidity 53%
Performance 53%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$193.09
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
-$7.58
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
63.364 B
YIELD 
N/A
SHARES OUTSTANDING 
328.277 M
DIVIDEND
$0.74
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$327,789,180
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO:
Region: US
Website: http://www.allergan.com
Employees: 17,400
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceuticals: Generic
Sector: Health Technology

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Recent news